Legal & General Group Plc Raises Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Legal & General Group Plc lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 395,311 shares of the biotechnology company’s stock after acquiring an additional 8,937 shares during the period. Legal & General Group Plc’s holdings in Arrowhead Pharmaceuticals were worth $26,245,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $32,000. WPG Advisers LLC increased its holdings in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ARWR. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Wall Street Zen cut Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. JPMorgan Chase & Co. assumed coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price on the stock. Finally, Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.80.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $77.91 on Monday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.26. The stock has a market cap of $10.97 billion, a price-to-earnings ratio of -36.24 and a beta of 1.28. The company’s 50 day moving average is $69.56 and its two-hundred day moving average is $64.57.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period in the prior year, the company posted $2.75 earnings per share. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. As a group, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.98 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 36,065 shares of company stock valued at $2,554,562 over the last ninety days. 3.60% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.